SEARCH

SEARCH BY CITATION

References

  • 1
    Blume-Jensen P & Hunter T (2001) Oncogenic kinase signalling. Nature 411, 355365.
  • 2
    Hallberg B & Palmer RH (2011) ALK and NSCLC: targeted therapy with ALK inhibitors. F1000 Med Rep 3, 21. doi: 10.3410/M3-21.
  • 3
    Maris JM, Hogarty MD, Bagatell R & Cohn SL (2007) Neuroblastoma. Lancet 369, 21062120.
  • 4
    Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362, 22022211.
  • 5
    Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G et al. (2008) Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967970.
  • 6
    Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P et al. (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930935.
  • 7
    Caren H, Abel F, Kogner P & Martinsson T (2008) High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 416, 153159.
  • 8
    Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang L, Soda M, Kikuchi A, Igarashi T et al. (2008) Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971974.
  • 9
    George RE, Sanda T, Hanna M, Frohling S, Luther W II, Zhang J, Ahn Y, Zhou W, London WB, McGrady P et al. (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975978.
  • 10
    Martinsson T, Eriksson T, Abrahamsson J, Caren H, Hansson M, Kogner P, Kamaraj S, Schonherr C, Weinmar J, Ruuth K et al. (2011) Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumour progression and unresponsiveness to therapy. Cancer Res 71, 98105.
  • 11
    Mosse YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ et al. (2013) Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol 14, 472480.
  • 12
    Kwak EL, Bang Y-J, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou S-HI, Dezube BJ, Jãnne PA, Costa DB et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363, 16931703.
  • 13
    Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N et al. (2010) Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 363, 17271733.
  • 14
    Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH III, Edeen PT et al. (2005) Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 102, 1101111016.
  • 15
    Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J & Sawyers CL (2002) Multiple BCR–ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117125.
  • 16
    Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN & Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification. Science 293, 876880.
  • 17
    Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG & Halmos B (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352, 786792.
  • 18
    Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG & Varmus H (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2, e73.
  • 19
    Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H et al. (2010) EML4–ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363, 17341739.
  • 20
    Doebele RC, Pilling AB, Aisner D, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA et al. (2012) Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 18, 14721482.
  • 21
    Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, Shakespeare WC, Iafrate AJ, Engelman JA & Shaw AT (2011) Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4–ALK. Proc Natl Acad Sci USA 108, 75357540.
  • 22
    Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop N, Wain JC, Yeo AT & Benes C et al. (2012) Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 4, 120ra17. doi:10.1126/scitranslmed.3003316.
  • 23
    Degoutin J, Vigny M & Gouzi JY (2007) ALK activation induces Shc and FRS2 recruitment: signaling and phenotypic outcomes in PC12 cell differentiation. FEBS Lett 581, 727734.
  • 24
    Chand D, Yamazaki Y, Ruuth K, Schonherr C, Martinsson T, Kogner P, Attiyeh EF, Maris J, Morozova O & Marra MA et al. (2012) Cell and Drosophila model systems define three classes of ALK mutations in neuroblastoma. Dis Models Mechanisms 6, 373382.
  • 25
    Crockett DK, Lin Z, Elenitoba-Johnson KS & Lim MS (2004) Identification of NPM–ALK interacting proteins by tandem mass spectrometry. Oncogene 23, 26172629.
  • 26
    Tanizaki J, Okamoto I, Takezawa K, Sakai K, Azuma K, Kuwata K, Yamaguchi H, Hatashita E, Nishio K, Janne PA et al. (2012) Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells. Br J Cancer 106, 763767.
  • 27
    Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, Levy DE & Inghirami G (2002) Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 21, 10381047.
  • 28
    Moog-Lutz C, Degoutin J, Gouzi JY, Frobert Y, Brunet-de Carvalho N, Bureau J, Creminon C & Vigny M (2005) Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J Biol Chem 280, 2603926048.
  • 29
    Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 11901203.
  • 30
    Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ, Zhang H, Zha XM, Polakiewicz RD & Comb MJ (2005) Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23, 94101.
  • 31
    Wang P, Wu F, Zhang J, McMullen T, Young LC, Ingham RJ, Li L & Lai R (2011) Serine phosphorylation of NPM–ALK, which is dependent on the auto-activation of the kinase activation loop, contributes to its oncogenic potential. Carcinogenesis 32, 146153.
  • 32
    Schonherr C, Yang HL, Vigny M, Palmer RH & Hallberg B (2010) Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells. Oncogene 29, 28172830.
  • 33
    Yang HL, Eriksson T, Vernersson E, Vigny M, Hallberg B & Palmer RH (2007) The ligand Jelly Belly (Jeb) activates the Drosophila Alk RTK to drive PC12 cell differentiation, but is unable to activate the mouse ALK RTK. J Exp Zool B Mol Dev Evol 308, 269282.
  • 34
    Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B, Vetharoy WR, Hallsworth A et al. (2012) The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell 22, 117130.
  • 35
    Heukamp LC, Thor T, Schramm A, De Preter K, Kumps C, De Wilde B, Odersky A, Peifer M, Lindner S, Spruessel A et al. (2012) Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Sci Transl Med 4, 141ra91.
  • 36
    Schonherr C, Ruuth K, Kamaraj S, Wang CL, Yang HL, Combaret V, Djos A, Martinsson T, Christensen JG, Palmer RH et al. (2012) Anaplastic lymphoma kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells. Oncogene 31, 51935200.
  • 37
    Zhu S, Lee JS, Guo F, Shin J, Perez-Atayde AR, Kutok JL, Rodig SJ, Neuberg DS, Helman D, Feng H et al. (2012) Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell 21, 362373.
  • 38
    Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M & Trent J (1983) Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305, 245248.
  • 39
    Cazes A, Louis-Brennetot C, Mazot P, Dingli F, Lombard B, Boeva V, Daveau R, Cappo J, Combaret V, Schleiermacher G et al. (2013) Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma. Cancer Res 73, 195204.
  • 40
    Schleiermacher G, Janoueix-Lerosey I, Combaret V, Derre J, Couturier J, Aurias A & Delattre O (2003) Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastoma. Cancer Genet Cytogenet 141, 3242.
  • 41
    Wei CC, Ball S, Lin L, Liu A, Fuchs JR, Li PK, Li C & Lin J (2011) Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells. Int J Oncol 38, 279285.
  • 42
    McMurray JS (2006) A new small-molecule Stat3 inhibitor. Chem Biol 13, 11231124.
  • 43
    Schust J, Sperl B, Hollis A, Mayer TU & Berg T (2006) Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 13, 12351242.
  • 44
    Donella-Deana A, Marin O, Cesaro L, Gunby RH, Ferrarese A, Coluccia AM, Tartari CJ, Mologni L, Scapozza L, Gambacorti-Passerini C et al. (2005) Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity. Biochemistry 44, 85338542.
  • 45
    Tartari CJ, Gunby RH, Coluccia AM, Sottocornola R, Cimbro B, Scapozza L, Donella-Deana A, Pinna LA & Gambacorti-Passerini C (2008) Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. J Biol Chem 283, 37433750.
  • 46
    Wang P, Wu F, Ma Y, Li L, Lai R & Young LC (2010) Functional characterization of the kinase activation loop in nucleophosmin (NPM)–anaplastic lymphoma kinase (ALK) using tandem affinity purification and liquid chromatography–mass spectrometry. J Biol Chem 285, 95103.
  • 47
    Bai RY, Dieter P, Peschel C, Morris SW & Duyster J (1998) Nucleophosmin–anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol 18, 69516961.
  • 48
    Fujimoto J, Shiota M, Iwahara T, Seki N, Satoh H, Mori S & Yamamoto T (1996) Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci USA 93, 41814186.
  • 49
    Chikamori M, Fujimoto J, Tokai-Nishizumi N & Yamamoto T (2007) Identification of multiple SNT-binding sites on NPM–ALK oncoprotein and their involvement in cell transformation. Oncogene 26, 29502954.
  • 50
    Zakrzewska M, Haugsten EM, Nadratowska-Wesolowska B, Oppelt A, Hausott B, Jin Y, Otlewski J, Wesche J & Wiedlocha A (2013) ERK-mediated phosphorylation of fibroblast growth factor receptor 1 on Ser777 inhibits signaling. Sci Signal 6, ra11.
  • 51
    Koese M, Rentero C, Kota BP, Hoque M, Cairns R, Wood P, Vila de Muga S, Reverter M, Alvarez-Guaita A, Monastyrskaya K et al. (2012) Annexin A6 is a scaffold for PKCalpha to promote EGFR inactivation. Oncogene 32, 28582872.
  • 52
    Blume-Jensen P, Jiang G, Hyman R, Lee KF, O'Gorman S & Hunter T (2000) Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3′-kinase is essential for male fertility. Nat Genet 24, 157162.
  • 53
    Palmer RH, Vernersson E, Grabbe C & Hallberg B (2009) Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 420, 345361.
  • 54
    Bresler SC, Wood AC, Haglund EA, Courtright J, Belcastro LT, Plegaria JS, Cole K, Toporovskaya Y, Zhao H, Carpenter EL et al. (2011) Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med 3, 108ra114.
  • 55
    Okubo J, Takita J, Chen Y, Oki K, Nishimura R, Kato M, Sanada M, Hiwatari M, Hayashi Y, Igarashi T et al. (2012) Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma. Oncogene 31, 46674676.
  • 56
    Schonherr C, Ruuth K, Yamazaki Y, Eriksson T, Christensen J, Palmer RH & Hallberg B (2011) Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684. Biochem J 440, 405413.
  • 57
    Hochgrafe F, Zhang L, O'Toole SA, Browne BC, Pinese M, Porta Cubas A, Lehrbach GM, Croucher DR, Rickwood D, Boulghourjian A et al. (2010) Tyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cells. Cancer Res 70, 93919401.
  • 58
    Cowley MJ, Pinese M, Kassahn KS, Waddell N, Pearson JV, Grimmond SM, Biankin AV, Hautaniemi S & Wu J (2012) PINA v2.0: mining interactome modules. Nucleic Acids Res 40, D862D865.
  • 59
    Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, Murray B, Latham V & Sullivan M (2012) PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res 40, D261D270.
  • 60
    Smoot ME, Ono K, Ruscheinski J, Wang PL & Ideker T (2011) Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27, 431432.
  • 61
    O'Brien J, Wilson I, Orton T & Pognan F (2000) Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267, 54215426.